Sartorius Stedim Biotech SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0013154002
EUR
205.20
-2.2 (-1.06%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Sartorius Stedim Biotech SA stock-summary
stock-summary
Sartorius Stedim Biotech SA
Pharmaceuticals & Biotechnology
Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The Company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Company Coordinates stock-summary
Company Details
Avenue de Jouques, Zone Industrielle les Paluds, C.S. 9105, Aubagne Cedex, AUBAGNE None : 13781
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 4 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Joachim Kreuzburg
Chairman of the Board and Chief Executive Officer, Chairman of the Executive Committee
Ms. Amelie Buton
Non-Executive Director, Employee Representative
Dr. Rene Faber
Non-Executive Director
Dr. Lothar Kappich
Non-Executive Director
Ms. Pascale Boissel
Non-Executive Independent Director
Ms. Susan Dexter
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
745 Million
(Quarterly Results - Jun 2025)
Net Profit:
69 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 20,186 Million ()

stock-summary
P/E

68.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.96%

stock-summary
Debt Equity

1.39

stock-summary
Return on Equity

7.77%

stock-summary
Price to Book

5.00